Acute myeloid leukemia
Conditions
Interventions
Control group:Placebo
Intervention group:Kidney tonifying and detoxifying herbs
Sponsors
Tongren Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
60 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Meeting the 2016 WHO diagnostic criteria for acute myeloid leukemia: peripheral blood and bone marrow primitive cells >= 20% or clonally recurrent genetic abnormalities t(8; 21)(q22; q22), inv16 (p13; q22) or t(16; 16)(p13; q22) and PML-RARA alpha, with primitive cells = 60 years; 3. Indication for chemotherapy; 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2; 5. No serious organ function abnormalities and the following test criteria: ALT, AST, TBIL = 55% by echocardiography; 6. Ability to understand and voluntarily give informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with contraindications to chemotherapy; 2. Pregnant or lactating women; 3. Patients with allergies to any of the drugs used in the study protocol; 4. Patients who are unable to sign informed consent due to mental retardation or psychiatric disorders; 5. Patients with other serious comorbidities such as severe impairment of vital organ function: respiratory failure, heart failure, decompensated hepatic insufficiency, renal insufficiency, etc., which in the judgment of the investigator would affect the study and make them unsuitable for enrollment; 6. Patients who participated in other relevant clinical studies during the same period or within 1 month prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bleeding score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Post-induction response (complete remission and partial remission) rate;Early death rate;Imported blood production;Infection incidence; | — |
Countries
China
Contacts
Public ContactLiu Ligen
Tongren Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed